Clinical Trial for Oral Formula of Vanillin and Wheat Germ Oil for Treatment of Mild and Moderate COVID-19 Viral Disease

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05157139

Enrollment

120

Registered

2021-12-14

Start date

2021-11-01

Completion date

2022-04-30

Last updated

2022-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild-to-moderate COVID-19

Keywords

mild-to-moderate COVID-19 vanillin, wheat germ oil

Brief summary

* The study is a randomized clinical trial to assess a natural formula of vanillin & wheat germ oil to treat and stop the clinical progression of COVID-19. * The study aims to treat people with mild-to-moderate COVID-19 before their cases become severe. * The study duration is a 5-day experimental intervention and an extended 4 weeks follow up.

Interventions

DRUGOral Capsule

Oral Capsule of vanillin & wheat germ oil

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. PCR confirmed diagnosis for COVID-19. 2. Age ≥18 years. 3. Both genders 4. The disease started within 7 days (ideally 72 hours) of diagnosis or clinical deterioration. 5. Patients diagnosed as mild or moderate

Exclusion criteria

1. Patients diagnosed with severe Illness: Individuals who have SpO2 \<92% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) \<300 mm Hg, respiratory frequency \>30 breaths/min, or lung infiltrates \>50%. 2. General: advanced kidney disease; advanced liver disease; pregnancy (known or potential) or lactation, and advanced cardiovascular diseases. 3. Allergy to Vanilla flavor, vanillin, or wheat germ oil 4. Active cancer

Design outcomes

Primary

Measure	Time frame	Description
1. Mean change in the disease severity (clinical assessment).	3-5 days	Time taken for the changes from moderate or mild or complete recovery/FDA assessment of key COVID-19-related symptoms score
2. Rate of disease remission.	3-5 days	For mild/moderate symptoms patients: fever, cough and other symptoms relieved
3. Hospitaization & Survival rate	up to 4 weeks	Comparing the influence of the intervention on the hospitalization & Survival rate followed for up to 4 weeks.

Secondary

Measure	Time frame	Description
4. Mean change in complete blood picture	3-5 days	CBC
5. Mean change in C reactive protein (CRP)	3-5 days	CRP
9. The mean change in serum interleukin-6 (IL-6)	3-5 days	serum IL-6

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026